Targeted therapy in SDH-deficient GIST

Area of Science:

• Oncology
• Gastroenterology
• Molecular Biology

Background:

• Advanced gastrointestinal stromal tumors (GIST) are often treated with tyrosine kinase inhibitors (TKIs) targeting KIT and PDGFRA mutations.
• A subset of GIST (5-10%) lacks these mutations and approximately half of these are deficient in succinate dehydrogenase (SDH).
• SDH deficiency promotes carcinogenesis via succinate accumulation and is associated with younger patients and hereditary syndromes.

Purpose of the Study:

• To provide a comprehensive overview of the current evidence on the medical treatment of SDH-deficient GIST.
• To address the urgent need for understanding disease mechanisms and treatment responses in this rare GIST subtype.
• To consolidate findings from an extensive literature search on SDH-deficient GIST management.

Main Methods:

• Extensive literature search on SDH-deficient GIST.
• Review of existing evidence on medical treatment patterns and responses.
• Analysis of disease mechanisms and therapeutic strategies.

Main Results:

• The role of TKIs in SDH-deficient GIST is controversial, with conflicting clinical results.
• SDH deficiency is linked to specific patient demographics and hereditary predispositions.
• Current evidence highlights the need for further research into effective therapies.

Conclusions:

• SDH-deficient GIST represents a distinct subtype with unique characteristics.
• The efficacy of current systemic therapies, including TKIs, remains uncertain for SDH-deficient GIST.
• Further investigation into novel therapeutic strategies and disease mechanisms is crucial for improving patient outcomes.